Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12061582 | 0.79 | MAOA (0.38) | MAOAMAOB | |
| SCHEMBL15901770 | 0.79 | MAOA (0.38) | MAOAMAOB | |
| SCHEMBL6684603 | 0.75 | MAOA (0.38) | MAOAMAOB | |
| SCHEMBL21872484 | 0.75 | MAOA (0.40) | MAOAMAOB | |
| SCHEMBL21084369 | 0.73 | MAOA (0.37) | MAOAMAOB | |
| SCHEMBL23261303 | 0.71 | LTA4H (0.31) | — | |
| SCHEMBL21426000 | 0.70 | MEN1 (0.34) | — | |
| SCHEMBL1028557 | 0.70 | — | — | |
| SCHEMBL25124849 | 0.70 | MEN1 (0.34) | — | |
| SCHEMBL4552340 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10611732-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| US-20190322628-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-24 | — | — | US | disclosed |
| US-10370340-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-9981919-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICAL N.V. (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170320835-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-04 | — | — | US | disclosed |
| US-9580392-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-28 | — | — | US | disclosed |
| US-9580392-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-28 | — | — | US | disclosed |
| US-9192577-B2 | Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-24 | — | — | US | disclosed |
| US-20140343006-A1 | HIV Replication Inhibiting Pyrimidines | JANSSEN PHARMACEUTICA NV (NL) | 2014-11-20 | — | — | US | disclosed |
| US-8828982-B2 | Pyrimidine derivatives for the prevention of HIV infection | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-09 | — | — | US | disclosed |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | GUILLEMONT JEROME EMILE GEORGES (FR) | 2012-03-29 | — | — | US | disclosed |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | GUILLEMONT JEROME EMILE GEORGES (FR) | 2012-03-29 | — | — | US | disclosed |
| US-8080551-B2 | HIV inhibiting pyrimidines derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-20 | — | — | US | disclosed |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | JANSSEN-CILAG (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | JANSSEN-CILAG (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | HEERES JAN | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343006-A1 | HIV Replication Inhibiting Pyrimidines | RRM2B, CCNO, RRM2 | MAOA 1016/4885MAOB 397/4885DPP4 3529/4885 |
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | MAOA 1016/4885MAOB 397/4885DPP4 3529/4885 |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | ADORA2B, CYP1B1, DPYD | MAOA 221/4885MAOB 46/4885DPP4 1593/4885 |
| US-20190322628-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | MAOA 1016/4885MAOB 397/4885DPP4 3529/4885 |
| US-10611732-B2 | HIV replication inhibiting pyrimidines | RRM2B, CCNO, RRM2 | MAOA 1016/4885MAOB 397/4885DPP4 3529/4885 |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | TYMS, PNP, DUT | MAOA 454/4885MAOB 206/4885DPP4 1974/4885 |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | NOX3, CBR3, CBR1 | MAOA 645/4885MAOB 393/4885DPP4 4168/4885 |
| US-10370340-B2 | HIV replication inhibiting pyrimidines | RRM2B, CCNO, RRM2 | MAOA 1016/4885MAOB 397/4885DPP4 3529/4885 |
| US-20170320835-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | MAOA 1016/4885MAOB 397/4885DPP4 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.